Table 8.
Cox’s regression analysis seeking risk factors for thrombosis in patients with myeloproliferative neoplasms (n = 335)
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Age > 60 years | 1.76 | 1.16–2.66 | 0.008 | 1.62 | 1.06–2.49 | 0.027 |
|
| ||||||
| Male sex | 1.25 | 1.02–1.53 | 0.031 | 1.67 | 1.11–2.52 | 0.014 |
|
| ||||||
| Palpable splenomegaly | 0.48 | 0.18–1.30 | 0.146 | - | - | - |
|
| ||||||
| WBC > 12.0 × 109/L | 1.28 | 0.87–1.89 | 0.207 | - | - | - |
|
| ||||||
| Platelets > 1,000 × 109/L | 0.94 | 0.60–1.49 | 0.794 | - | - | - |
|
| ||||||
| LDH > 1.5 × UNL | 0.82 | 0.50–1.35 | 0.441 | - | - | - |
|
| ||||||
| Positive for JAK2V617F | 1.94 | 1.05–3.58 | 0.035 | 1.23 | 0.77–1.98 | 0.199 |
|
| ||||||
| ET | 0.91 | 0.61–1.35 | 0.634 | - | - | - |
|
| ||||||
| Pre-PMF | 1.37 | 0.75–2.16 | 0.681 | - | - | - |
|
| ||||||
| PV | 1.24 | 0.84–1.83 | 0.274 | - | - | - |
|
| ||||||
| Hypertension | 1.71 | 1.16–2.52 | 0.007 | 1.59 | 1.06–2.36 | 0.024 |
|
| ||||||
| Diabetes mellitus | 1.36 | 0.86–2.17 | 0.193 | - | - | - |
|
| ||||||
| Chronic kidney disease | 1.50 | 0.96–2.34 | 0.072 | 1.11 | 0.70–1.78 | 0.659 |
|
| ||||||
| Smoking | 1.66 | 1.11–2.48 | 0.013 | 1.36 | 0.87–2.13 | 0.181 |
HR, hazard ratio; CI, confidence interval; WBC, white blood cell; LDH, lactate dehydrogenase; UNL, upper normal limit; JAK2, Janus kinase 2; ET, essential thrombocythemia; pre-PMF, prefibrotic/early primary myelofibrosis; PV, polycythemia vera.